estrogen etc - meaning and definition. What is estrogen etc
Diclib.com
Online Dictionary

What (who) is estrogen etc - definition

MEDICAL CONDITION
Complete estrogen insensitivity syndrome; Partial estrogen insensitivity syndrome; Mild estrogen insensitivity syndrome; CEIS; Estrogen insensitivity; Estrogen resistance; Oestrogen insensitivity syndrome

ETC (Chilean TV channel)         
CHILEAN CABLE TELEVISION CHANNEL
Etc...TV; Etc TV; ETC (Chilean TV network)
ETC is a Chilean cable television channel currently owned by Mega. The channel's slogan is "Todo pasa por Etc...
Antiestrogen         
COMPOUND WHICH INHIBITS OR ANTAGONIZES THE ACTION OR BIOSYNTHESIS OF ESTROGENIC COMPOUNDS
Estradiol antagonists; Estrogen antagonists; Anti-estrogen; Estrogen antagonist; Anti-estrogenic; Antiestrogenic; Estrogen blockers; Estrogen blocker; Estradiol antagonist; Antiestrogens; Anti-estrogens; Estradiol blocker; Estradiol blockers; Estrogen receptor antagonists; Estrogen receptor antagonist; Estradiol receptor antagonist; Estradiol receptor antagonists; Estradiol receptor blocker; Estradiol receptor blockers; Estrogen receptor blockers; Estrogen receptor blocker; ER blocker; ER blockers; ER antagonist; ER antagonists; Oestrogen blockers; Oestrogen blocker
Antiestrogens, also known as estrogen antagonists or estrogen blockers, are a class of drugs which prevent estrogens like estradiol from mediating their biological effects in the body. They act by blocking the estrogen receptor (ER) and/or inhibiting or suppressing estrogen production.
Selective estrogen receptor modulator         
  •  4-Hydroxytamoxifen (red) overlaid with 17β-estradiol (black)
  •  Bazedoxifene includes an indole system (red) which is connected to an amine through a benzyloxyethyl chain (green).
  •  ''trans''-Form of clomifene with the triphenylethylene structure in red.
  •  Chemical structure of lasofoxifene shows cis-oriented phenyls.
  •  Chemical structure of nafoxidine with the dihydronapthalene group in red.
  • UK]])
  •  Chemical structure of ospemifene. Ethoxy side chain ends with a hydroxy group (red) instead of a dimethylamino group as with first-generation SERMs.
  • "A ring" (A) and "D ring" (D) marked in raloxifene.
GROUP OF COMPOUNDS ABLE TO BIND AND ACTIVATE ESTROGEN RECEPTORS, BUT ACTING AS EITHER AN AGONIST OR ANTAGONIST
Selective oestrogen receptor modulator; Selective estrogen receptor modulators; Oestrogen receptor beta; Selective oestrogen receptor modulators; Selective ER modulator; Selective Estrogen Receptor Modulators (SERMs); Estrogen-receptor modulator; Selective estrogen-receptor modulator; Discovery and development of selective estrogen receptor modulators; Draft:Selective estrogen receptor modulator; Estrogen receptor agonist/antagonist; ERAA; Estrogen receptor agonists/antagonists; Estrogen receptor agonist/antagonists
Selective estrogen receptor modulators (SERMs), also known as estrogen receptor agonist/antagonists (ERAAs), are a class of drugs that act on the estrogen receptor (ER). A characteristic that distinguishes these substances from pure ER agonists and antagonists (that is, full agonists and silent antagonists) is that their action is different in various tissues, thereby granting the possibility to selectively inhibit or stimulate estrogen-like action in various tissues.

Wikipedia

Estrogen insensitivity syndrome

Estrogen insensitivity syndrome (EIS), or estrogen resistance, is a form of congenital estrogen deficiency or hypoestrogenism which is caused by a defective estrogen receptor (ER) – specifically, the estrogen receptor alpha (ERα) – that results in an inability of estrogen to mediate its biological effects in the body. Congenital estrogen deficiency can alternatively be caused by a defect in aromatase, the enzyme responsible for the biosynthesis of estrogens, a condition which is referred to as aromatase deficiency and is similar in symptomatology to EIS.

EIS is an extremely rare occurrence. As of 2016, there have been three published reports of EIS, involving a total of five individuals. The reports include a male case published in 1994, a female case published in 2013, and a familial case involving two sisters and a brother which was published in 2016.

EIS is analogous to androgen insensitivity syndrome (AIS), a condition in which the androgen receptor (AR) is defective and insensitive to androgens, such as testosterone and dihydrotestosterone (DHT). The functional opposite of EIS is hyperestrogenism, for instance that seen in aromatase excess syndrome.